Immunic Inc (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced on Friday that it has promoted Glenn Whaley, principal accounting officer and controller, to the position of vice president finance, effective immediately.
The company added that its chief financial officer, Sanjay S. Patel, CFA, has resigned to pursue opportunities in the nonprofit sector.
Whaley is to assume day-to-day financial management responsibilities, and will report directly to Daniel Vitt, PhD, chief executive officer and president.
Also with effect from 17 April 2020, Immunic's current chairman of the board of directors, Duane Nash, MD, JD, MBA, will temporarily assume the role of executive chairman.
Vitt stated: "We are pleased to have promoted Glenn to vice president finance, as he has proven to be instrumental in running our U.S. operations and financial reporting functions. As such, we are confident that under his leadership, operations will continue in a seamless fashion. I very much look forward to continuing to work closely with both Glenn and Duane as we further develop the company and advance our pipeline of three highly attractive small molecule candidates. In addition, I wish Sanjay the best for his future endeavours."
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca